A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Inclusion criteria

• Healthy male or female 18 to 65 years of age at Screening, inclusive
• Body mass index (BMI) 18.5 to 32 kg/m^2, inclusive
• Body weight 50 to 100 kg, inclusive
• Females must be of non-childbearing potential
• Males of reproductive potential must agree to remain abstinent or must be using highly effective contraception and must avoid sperm donation, from Screening until at least 8 weeks after the last study drug administration or until study completion, whichever is later

Exclusion criteria

• Significant medical history, psychiatric disorder, or acute infection at Screening (as determined by Investigator)
• History of alcoholism or drug addiction within 6 months prior to CRU Check-in
• Use of tobacco or nicotine-containing products from 6 months prior to CRU Check-in and during the study
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred wtihin 30 days or 5 half-lives, whichever is longer, prior to CRU Check-in